SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-346374"
 

Search: onr:"swepub:oai:DiVA.org:uu-346374" > Persistent preventi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®) : a placebo-controlled randomised phase II study (PLIANT)

Glimelius, Bengt (author)
Uppsala universitet,Experimentell och klinisk onkologi
Manojlovic, Nebojsa (author)
Mil Med Acad Serbia, Clin Gastroenterol & Hepatol, Belgrade
Pfeiffer, Per (author)
Odense Univ Hosp, Dept Oncol, Odense
show more...
Mosidze, Baadur (author)
Univ Clin, LTD High Technol Med Ctr, Tbilisi
Kurteva, Galina (author)
SHATO EAD, Clin Chemotherapy, Sofia
Karlberg, Mia (author)
Karolinska Inst, Dept Pathol & Oncol, Stockholm
Mahalingam, Devalingam (author)
Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio
Buhl Jensen, Peter (author)
Buhl Oncol, Copenhagen.; PledPharma AB, Stockholm
Kowalski, Jan (author)
JK Biostat, Stockholm
Bengtson, Marie (author)
PledPharma AB, Stockholm
Nittve, Malin (author)
PledPharma AB, Stockholm
Nässtrom, Jacques (author)
PledPharma AB, Stockholm
show less...
 (creator_code:org_t)
2018
2018
English.
In: Acta Oncologica. - 0284-186X .- 1651-226X. ; 57:3, s. 393-402
Related links:
https://urn.kb.se/re...
show more...
https://doi.org/10.1...
http://kipublication...
show less...
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Purpose: Oxaliplatin causes disabling acute and chronic peripheral neuropathy. We explored the preventive effects of calmangafodipir, mimicking the mitochondrial enzyme manganese superoxide dismutase, thereby protecting cells from oxidative stress, in a placebo-controlled, double-blinded randomised phase II study (ClinicalTrials.gov.NCT01619423) in patients with metastatic colorectal cancer (mCRC).Patient and methods: mCRC patients treated with modified FOLFOX-6 (folinic acid 200 mg/m2, 5-fluorouracil bolus 400 mg/m2, oxaliplatin 85 mg/m2 and 5-fluorouracil 2400 mg/m2 continuous infusion for 46 h) every fortnight for 8 cycles in first or second line were eligible. Calmangafodipir was given in a phase I dose-finding and in a phase II placebo-controlled study, as a 5-min infusion 10 min prior to oxaliplatin. Neurotoxicity was evaluated by the physician using the Oxaliplatin Sanofi Specific Scale and by the patient using the cold allodynia test and the Leonard scale.Results: Eleven patients were included in phase I without any detectable toxicity to calmangafodipir. In the phase II study, 173 patients were randomised to placebo (n = 60), calmangafodipir 2 µmol/kg (n = 57) and calmangafodipir 5 µmol/kg (n = 45, initially 10 µmol/kg, n = 11). Calmangafodipir-treated patients (all three doses pooled) had less physician graded neurotoxicity (odds ratio (90% confidence interval one-sided upper level) 0.62(1.15), p = .16), significantly less problems with cold allodynia (mean 1.6 versus 2.3, p < .05) and significantly fewer sensory symptoms in the Leonard scale (cycle 1–8 mean 1.9 versus 3.0, p < .05 and during follow-up after 3 and 6 months, mean 3.5 versus 7.3, p < .01). Response rate, progression-free and overall survival did not differ among groups.Conclusions: Calmangafodipir at a dose of 5 µmol/kg appears to prevent the development of oxaliplatin-induced acute and delayed CIPN without apparent influence on tumour outcomes.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view